Standard
The effect of liraglutide on cardiac autonomic function in type 2 diabetes : A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial. / Sivalingam, Suvanjaa; Hein Zobel, Emilie; Hansen, Christian S.; Ripa, Rasmus S.; von Scholten, Bernt J.; Rotbain Curovic, Viktor; Kjaer, Andreas; Jensen, Jacob K.; Hansen, Tine W.; Rossing, Peter.
In:
Diabetes, Obesity and Metabolism, Vol. 24, No. 8, 2022, p. 1638-1642.
Research output: Contribution to journal › Letter › Research › peer-review
Harvard
Sivalingam, S, Hein Zobel, E, Hansen, CS
, Ripa, RS, von Scholten, BJ, Rotbain Curovic, V
, Kjaer, A, Jensen, JK, Hansen, TW
& Rossing, P 2022, '
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial',
Diabetes, Obesity and Metabolism, vol. 24, no. 8, pp. 1638-1642.
https://doi.org/10.1111/dom.14717APA
Sivalingam, S., Hein Zobel, E., Hansen, C. S.
, Ripa, R. S., von Scholten, B. J., Rotbain Curovic, V.
, Kjaer, A., Jensen, J. K., Hansen, T. W.
, & Rossing, P. (2022).
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
Diabetes, Obesity and Metabolism,
24(8), 1638-1642.
https://doi.org/10.1111/dom.14717Vancouver
Sivalingam S, Hein Zobel E, Hansen CS
, Ripa RS, von Scholten BJ, Rotbain Curovic V et al.
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
Diabetes, Obesity and Metabolism. 2022;24(8):1638-1642.
https://doi.org/10.1111/dom.14717Author
Sivalingam, Suvanjaa ; Hein Zobel, Emilie ; Hansen, Christian S. ; Ripa, Rasmus S. ; von Scholten, Bernt J. ; Rotbain Curovic, Viktor ; Kjaer, Andreas ; Jensen, Jacob K. ; Hansen, Tine W. ; Rossing, Peter. / The effect of liraglutide on cardiac autonomic function in type 2 diabetes : A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial. In: Diabetes, Obesity and Metabolism. 2022 ; Vol. 24, No. 8. pp. 1638-1642.
Bibtex
@article{57e7583998c24cf195a3d9e832ee6194,
title = "The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial",
author = "Suvanjaa Sivalingam and {Hein Zobel}, Emilie and Hansen, {Christian S.} and Ripa, {Rasmus S.} and {von Scholten}, {Bernt J.} and {Rotbain Curovic}, Viktor and Andreas Kjaer and Jensen, {Jacob K.} and Hansen, {Tine W.} and Peter Rossing",
note = "Funding Information: PR has received consultancy and/or speaking fees to Steno Diabetes Centre Copenhagen from Novo Nordisk, Vifor, Sanofi Aventis, Boehringer Ingelheim, Eli Lilly, Gilead, Astellas, AstraZeneca, Bayer, MSD and Mundipharma. PR has received research grants from AstraZeneca and Novo Nordisk and has had shares in Novo Nordisk. AK has received consultancy fees from Novo Nordisk. RSR has shares in Novo Nordisk. BJvS is now an employee at Novo Nordisk. The other authors declare that there is no duality of interest associated with this manuscript. Funding Information: information University of Copenhagen; Novo Nordisk We thank all participants and we acknowledge the work of study nurse L. Jelstrup and laboratory technicians D. Riis, T. R. Juhl and J. A. Hermann (Steno Diabetes Centre Copenhagen, Herlev, Denmark). The study was funded by Novo Nordisk A/S and Skibsreder Per Henriksen, R. og hustrus fund. The study also received internal funding from Steno Diabetes Centre Copenhagen and Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Denmark. Funding Information: We thank all participants and we acknowledge the work of study nurse L. Jelstrup and laboratory technicians D. Riis, T. R. Juhl and J. A. Hermann (Steno Diabetes Centre Copenhagen, Herlev, Denmark). The study was funded by Novo Nordisk A/S and Skibsreder Per Henriksen, R. og hustrus fund. The study also received internal funding from Steno Diabetes Centre Copenhagen and Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Denmark. ",
year = "2022",
doi = "10.1111/dom.14717",
language = "English",
volume = "24",
pages = "1638--1642",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "8",
}
RIS
TY - JOUR
T1 - The effect of liraglutide on cardiac autonomic function in type 2 diabetes
T2 - A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial
AU - Sivalingam, Suvanjaa
AU - Hein Zobel, Emilie
AU - Hansen, Christian S.
AU - Ripa, Rasmus S.
AU - von Scholten, Bernt J.
AU - Rotbain Curovic, Viktor
AU - Kjaer, Andreas
AU - Jensen, Jacob K.
AU - Hansen, Tine W.
AU - Rossing, Peter
N1 - Funding Information:
PR has received consultancy and/or speaking fees to Steno Diabetes Centre Copenhagen from Novo Nordisk, Vifor, Sanofi Aventis, Boehringer Ingelheim, Eli Lilly, Gilead, Astellas, AstraZeneca, Bayer, MSD and Mundipharma. PR has received research grants from AstraZeneca and Novo Nordisk and has had shares in Novo Nordisk. AK has received consultancy fees from Novo Nordisk. RSR has shares in Novo Nordisk. BJvS is now an employee at Novo Nordisk. The other authors declare that there is no duality of interest associated with this manuscript.
Funding Information:
information University of Copenhagen; Novo Nordisk We thank all participants and we acknowledge the work of study nurse L. Jelstrup and laboratory technicians D. Riis, T. R. Juhl and J. A. Hermann (Steno Diabetes Centre Copenhagen, Herlev, Denmark). The study was funded by Novo Nordisk A/S and Skibsreder Per Henriksen, R. og hustrus fund. The study also received internal funding from Steno Diabetes Centre Copenhagen and Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Denmark.
Funding Information:
We thank all participants and we acknowledge the work of study nurse L. Jelstrup and laboratory technicians D. Riis, T. R. Juhl and J. A. Hermann (Steno Diabetes Centre Copenhagen, Herlev, Denmark). The study was funded by Novo Nordisk A/S and Skibsreder Per Henriksen, R. og hustrus fund. The study also received internal funding from Steno Diabetes Centre Copenhagen and Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Denmark.
PY - 2022
Y1 - 2022
U2 - 10.1111/dom.14717
DO - 10.1111/dom.14717
M3 - Letter
C2 - 35415938
AN - SCOPUS:85129817475
VL - 24
SP - 1638
EP - 1642
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 8
ER -
